Free Trial Information
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...XRCC1 AURKA; p53 AURKB p53-mutant head and neck cancer 5814 Chk1 TTK Proliferation regulation DDR PI3KCB...
Read More
BioCentury | Nov 3, 2016
Translation in Brief

One plus one equals four

...month, the compound - a dual inhibitor of phosphoinositide 3-kinase catalytic subunit β polypeptide ( PI3KCB...
...the clinical candidate. -Karen Tkach Karen Tkach KA2237 Karus Therapeutics Ltd. Phosphoinositide 3-kinase (PI3K) catalytic subunit alpha polypeptide (PI3KCA) (p110alpha) Phosphoinositide 3-kinase (PI3K) catalytic subunit beta polypeptide (PI3KCB) (p110beta) Phosphoinositide...
Read More
BioCentury | Oct 17, 2016
Clinical News

KA2237: Phase I started

...target: Phosphoinositide 3-kinase (PI3K) catalytic subunit beta polypeptide (PI3KCB) (p110beta) ; Phosphoinositide 3-kinase (PI3K) catalytic subunit delta polypeptide (PI3KCD) (p110delta) Description: Phosphoinositide 3-kinase (PI3K) catalytic subunit beta polypeptide (PI3KCB; p110beta...
Read More
BioCentury | Sep 21, 2009
Emerging Company Profile

Xcovery: Taking tox out

...MAPK14 ) inhibitor in preclinical testing for inflammation. The company also has discovery programs with PI3KCB...
Read More
Items per page:
1 - 4 of 4